Neurocrine Biosciences Stock Cash Flow From Operations

NBIX Stock

USD 142.89 0.14 0.1%

Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Neurocrine Biosciences Company Cash Flow From Operations Analysis

Neurocrine Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current Neurocrine Biosciences Cash Flow From Operations

389.9 M

Most of Neurocrine Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Neurocrine Cash Flow From Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.39	0.47	0.98	0.97	0.96	0.99	0.52	0.87	0.93	0.79	0.58	0.91	0.8	0.97	0.84	0.54	0.97	-0.8	0.62	-0.72	0.77	0.92
Total Stockholder Equity	0.99		0.32	0.54	0.98	0.99	0.91	0.97	0.46	0.87	0.9	0.71	0.55	0.88	0.84	0.99	0.81	0.5	0.95	-0.85	0.6	-0.71	0.8	0.94
Net Debt	0.39	0.32		-0.03	0.43	0.38	0.5	0.41	0.74	0.13	0.41	0.57	0.21	0.43	0.34	0.23	0.39	0.31	0.49	0.15	0.09	-0.17	-0.05	0.19
Retained Earnings	0.47	0.54	-0.03		0.55	0.58	0.3	0.39	0.02	0.48	0.27	0.01	-0.29	0.36	0.65	0.54	0.1	0.2	0.46	-0.68	0.33	-0.27	0.55	0.63
Accounts Payable	0.98	0.98	0.43	0.55		0.99	0.93	0.96	0.6	0.84	0.9	0.72	0.48	0.88	0.85	0.94	0.78	0.51	0.95	-0.77	0.59	-0.63	0.71	0.93
Net Receivables	0.97	0.99	0.38	0.58	0.99		0.89	0.96	0.53	0.83	0.9	0.68	0.48	0.85	0.9	0.96	0.76	0.47	0.93	-0.81	0.54	-0.65	0.77	0.93
Total Liab	0.96	0.91	0.5	0.3	0.93	0.89		0.96	0.62	0.83	0.92	0.92	0.6	0.92	0.67	0.87	0.86	0.6	0.94	-0.65	0.63	-0.71	0.64	0.83
Total Current Assets	0.99	0.97	0.41	0.39	0.96	0.96	0.96		0.56	0.86	0.97	0.83	0.63	0.92	0.79	0.95	0.88	0.57	0.93	-0.74	0.53	-0.74	0.76	0.88
Short Term Debt	0.52	0.46	0.74	0.02	0.6	0.53	0.62	0.56		0.33	0.64	0.62	0.34	0.56	0.37	0.32	0.51	0.4	0.51	0.01	0.19	-0.08	-0.02	0.34
Intangible Assets	0.87	0.87	0.13	0.48	0.84	0.83	0.83	0.86	0.33		0.79	0.67	0.48	0.9	0.62	0.88	0.73	0.64	0.78	-0.78	0.55	-0.77	0.81	0.82
Short Term Investments	0.93	0.9	0.41	0.27	0.9	0.9	0.92	0.97	0.64	0.79		0.83	0.65	0.89	0.72	0.86	0.86	0.59	0.84	-0.62	0.47	-0.72	0.69	0.79
Long Term Debt	0.79	0.71	0.57	0.01	0.72	0.68	0.92	0.83	0.62	0.67	0.83		0.63	0.85	0.42	0.67	0.84	0.63	0.77	-0.38	0.46	-0.67	0.48	0.59
Common Stock	0.58	0.55	0.21	-0.29	0.48	0.48	0.6	0.63	0.34	0.48	0.65	0.63		0.58	0.25	0.55	0.87	0.44	0.51	-0.3	0.45	-0.53	0.49	0.49
Property Plant Equipment	0.91	0.88	0.43	0.36	0.88	0.85	0.92	0.92	0.56	0.9	0.89	0.85	0.58		0.57	0.86	0.87	0.69	0.84	-0.61	0.53	-0.79	0.7	0.77
Current Deferred Revenue	0.8	0.84	0.34	0.65	0.85	0.9	0.67	0.79	0.37	0.62	0.72	0.42	0.25	0.57		0.83	0.52	0.25	0.78	-0.76	0.3	-0.5	0.72	0.82
Net Tangible Assets	0.97	0.99	0.23	0.54	0.94	0.96	0.87	0.95	0.32	0.88	0.86	0.67	0.55	0.86	0.83		0.8	0.46	0.91	-0.89	0.56	-0.76	0.87	0.93
Capital Surpluse	0.84	0.81	0.39	0.1	0.78	0.76	0.86	0.88	0.51	0.73	0.86	0.84	0.87	0.87	0.52	0.8		0.64	0.78	-0.52	0.57	-0.7	0.68	0.74
Deferred Long Term Liab	0.54	0.5	0.31	0.2	0.51	0.47	0.6	0.57	0.4	0.64	0.59	0.63	0.44	0.69	0.25	0.46	0.64		0.46	-0.25	0.44	-0.58	0.47	0.48
Long Term Investments	0.97	0.95	0.49	0.46	0.95	0.93	0.94	0.93	0.51	0.78	0.84	0.77	0.51	0.84	0.78	0.91	0.78	0.46		-0.76	0.69	-0.64	0.67	0.91
Long Term Debt Total	-0.8	-0.85	0.15	-0.68	-0.77	-0.81	-0.65	-0.74	0.01	-0.78	-0.62	-0.38	-0.3	-0.61	-0.76	-0.89	-0.52	-0.25	-0.76		-0.58	0.61	-0.86	-0.89
Net Invested Capital	0.62	0.6	0.09	0.33	0.59	0.54	0.63	0.53	0.19	0.55	0.47	0.46	0.45	0.53	0.3	0.56	0.57	0.44	0.69	-0.58		-0.45	0.46	0.76
Short Long Term Debt	-0.72	-0.71	-0.17	-0.27	-0.63	-0.65	-0.71	-0.74	-0.08	-0.77	-0.72	-0.67	-0.53	-0.79	-0.5	-0.76	-0.7	-0.58	-0.64	0.61	-0.45		-0.85	-0.65
Net Working Capital	0.77	0.8	-0.05	0.55	0.71	0.77	0.64	0.76	-0.02	0.81	0.69	0.48	0.49	0.7	0.72	0.87	0.68	0.47	0.67	-0.86	0.46	-0.85		0.82
Capital Stock	0.92	0.94	0.19	0.63	0.93	0.93	0.83	0.88	0.34	0.82	0.79	0.59	0.49	0.77	0.82	0.93	0.74	0.48	0.91	-0.89	0.76	-0.65	0.82

Click cells to compare fundamentals

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Competition

Predict Neurocrine Biosciences

Total Cash From Operating Activities Over Time

In accordance with the recently published financial statements, Neurocrine Biosciences has 389.9 M in Cash Flow From Operations. This is 26.05% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash flow from operations for all United States stocks is 59.85% higher than that of the company.

Neurocrine Cash Flow From Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.

Neurocrine Biosciences is currently under evaluation in cash flow from operations category among related companies.

Neurocrine Fundamentals

	Return On Equity	0.13
	Return On Asset	0.0878
	Profit Margin	0.13 %
	Operating Margin	0.29 %
	Current Valuation	13.12 B
	Shares Outstanding	100.58 M
	Shares Owned By Insiders	1.00 %
	Shares Owned By Institutions	94.68 %
	Number Of Shares Shorted	2.02 M
	Price To Earning	202.90 X
	Price To Book	6.07 X
	Price To Sales	7.18 X
	Revenue	1.89 B
	Gross Profit	1 B
	EBITDA	416.1 M
	Net Income	249.7 M
	Cash And Equivalents	799.4 M
	Cash Per Share	8.31 X
	Total Debt	428.4 M
	Debt To Equity	0.18 %
	Current Ratio	2.48 X
	Book Value Per Share	22.61 X
	Cash Flow From Operations	389.9 M
	Short Ratio	2.26 X
	Earnings Per Share	2.47 X
	Price To Earnings To Growth	0.44 X
	Target Price	153.29
	Number Of Employees	1.4 K
	Beta	0.28
	Market Capitalization	13.83 B
	Total Asset	3.25 B
	Retained Earnings	(157.1 M)
	Working Capital	952.2 M
	Current Asset	384.07 M
	Current Liabilities	25.71 M
	Net Asset	3.25 B

About Neurocrine Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:

How To Invest In Neurocrine

Details

Is Neurocrine Stock a good investment?

Details

What is Neurocrine Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Neurocrine Biosciences Piotroski F Score and Neurocrine Biosciences Altman Z Score analysis.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	CEOs Directory Screen CEOs from public companies around the world
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.648

Earnings Share

2.47

Revenue Per Share

19.315

Quarterly Revenue Growth

0.25

Return On Assets

0.0878

The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Biosciences Stock Cash Flow From Operations

Neurocrine Biosciences Company Cash Flow From Operations Analysis

Operating Cash Flow

EBITDA

-

Taxes

Current Neurocrine Biosciences Cash Flow From Operations

Neurocrine Cash Flow From Operations Driver Correlations

Neurocrine Cash Flow From Operations Peer Comparison

Neurocrine Fundamentals

About Neurocrine Biosciences Fundamental Analysis

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Neurocrine Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY